No Data
We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Citi Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Cuts Target Price to $13
Citi Sticks to Its Buy Rating for Oric Pharmaceuticals (ORIC)
Oppenheimer Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $15
Stifel Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $20
JonesTrading Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $17
loading...